EXO1 Overexpression Creates BRCA-like DNA Instability in 20-30% of Breast and Ovarian Cancers

The study combined TCGA pan-cancer analysis with controlled overexpression experiments in human cell lines. Elevated EXO1 occurred in 20-30% of breast, ovarian, melanoma, and hepatobiliary tumors and correlated with basal-like breast cancer; functional assays showed that excess EXO1 nuclease activity, not protein presence alone, drove double-strand break accumulation. This mechanism expands the population eligible for PARP-inhibitor or platinum therapy beyond germline BRCA carriers, addressing a gap in current biomarker panels that rely solely on mutation status.

Prior TCGA and ICGC studies noted EXO1 upregulation but lacked mechanistic follow-up; the Penn State work supplies the missing causal link by disabling EXO1 catalytic activity and confirming lesion formation. It also highlights why BRCA-wild-type patients sometimes respond to PARP inhibitors, an observation often dismissed as off-target effects rather than replication-fork vulnerability.

Next steps require prospective trials stratifying EXO1-high patients by quantitative protein or mRNA thresholds and measuring objective response rates to olaparib or carboplatin. Parallel CRISPR screens could identify synthetic-lethal partners that further exploit the fork-degradation phenotype.

Validation in patient-derived organoids and larger cohorts will determine whether EXO1 expression assays can be integrated into existing HRD scoring systems without inflating false positives.